On 31 August 2023, Coloplast completed the acquisition of the Icelandic business Kerecis at an amount of approx. DKK 8.9bn. Kerecis is an innovative and fast-growing business within the biologics wound care segment and has developed a technology in which fish skin may be used as a method for wound care.
To begin with, the acquisition price was financed through a DKK 8.2bn bridge-to-equity loan, which was granted by Danske Bank A/S and Nordea Danmark, Fillial af Nordea bank Abp, Finland (as joint mandated lead arrangers, underwriters, bookrunner and original lenders).
Accura advised Danske Bank A/S and Nordea Danmark, Filial af Nordea Bank Abp, Finland in connection with the granting of and the payment under the bridge-to-equity loan.
Accura also advised the banks in connection with the following issue of new B shares in Coloplast.